U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C10H9N4O2S.Zn
Molecular Weight 563.947
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SULFADIAZINE ZINC

SMILES

[Zn++].NC1=CC=C(C=C1)S(=O)(=O)[N-]C2=NC=CC=N2.NC3=CC=C(C=C3)S(=O)(=O)[N-]C4=NC=CC=N4

InChI

InChIKey=RXXROIWDLGTUIN-UHFFFAOYSA-N
InChI=1S/2C10H9N4O2S.Zn/c2*11-8-2-4-9(5-3-8)17(15,16)14-10-12-6-1-7-13-10;/h2*1-7H,11H2;/q2*-1;+2

HIDE SMILES / InChI

Molecular Formula Zn
Molecular Weight 65.409
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C10H10N4O2S
Molecular Weight 250.277
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/dosage/sulfadiazine.html

Sulfadiazine is a sulfonamide antibiotic. The sulfonamides are synthetic bacteriostatic antibiotics with a wide spectrum against most gram-positive and many gram-negative organisms. However, many strains of an individual species may be resistant. Sulfonamides inhibit multiplication of bacteria by acting as competitive inhibitors of p-aminobenzoic acid in the folic acid metabolism cycle. Bacterial sensitivity is the same for the various sulfonamides, and resistance to one sulfonamide indicates resistance to all. Most sulfonamides are readily absorbed orally. However, parenteral administration is difficult, since the soluble sulfonamide salts are highly alkaline and irritating to the tissues. The sulfonamides are widely distributed throughout all tissues. High levels are achieved in pleural, peritoneal, synovial, and ocular fluids. Although these drugs are no longer used to treat meningitis, CSF levels are high in meningeal infections. Their antibacterial action is inhibited by pus. Sulfadiazine is a competitive inhibitor of the bacterial enzyme dihydropteroate synthetase. This enzyme is needed for the proper processing of para-aminobenzoic acid (PABA) which is essential for folic acid synthesis. The inhibited reaction is necessary in these organisms for the synthesis of folic acid. Used for the treatment of rheumatic fever and meningococcal meningitis.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Sulfadiazine

Approved Use

Sulfadiazine tablets USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris. Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum, when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilusinfluenzae, when used concomitantly with adequate doses of penicillin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin.

Launch Date

1994
Curative
Sulfadiazine

Approved Use

Sulfadiazine tablets USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris. Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum, when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilusinfluenzae, when used concomitantly with adequate doses of penicillin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin.

Launch Date

1994
Curative
Sulfadiazine

Approved Use

Sulfadiazine tablets USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris. Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum, when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilusinfluenzae, when used concomitantly with adequate doses of penicillin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin.

Launch Date

1994
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
84.9 μg/mL
2 g 2 times / day steady-state, oral
dose: 2 g
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SULFADIAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.247 μg × h/mL
2 g 2 times / day steady-state, oral
dose: 2 g
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SULFADIAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
11.9 h
2 g 2 times / day steady-state, oral
dose: 2 g
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
SULFADIAZINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Disc. AE: Stenocardia, Distress gastrointestinal...
Other AEs: Thrombopenia, Creatinine serum increased...
AEs leading to
discontinuation/dose reduction:
Stenocardia (grade 3, 5%)
Distress gastrointestinal (grade 3, 5%)
Skin rash (grade 3, 5%)
Other AEs:
Thrombopenia (9%)
Creatinine serum increased (5%)
Elevated liver enzyme levels (5%)
Malaise (23%)
Diarrhea (5%)
Sources: Page: p.36, 38
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Disc. AE: Stevens Johnson syndrome, Thrombocytopenia...
Other AEs: Skin rash, Neutropenia...
AEs leading to
discontinuation/dose reduction:
Stevens Johnson syndrome (grade 3, 1.16%)
Thrombocytopenia (grade 4, 25%)
Major bleed (grade 4, 25%)
Other AEs:
Skin rash (1.16%)
Neutropenia (18.75%)
Febrile neutropenia (1.16%)
Sources: Page: p.4
6 g 1 times / day steady, oral (max)
Recommended
Dose: 6 g, 1 times / day
Route: oral
Route: steady
Dose: 6 g, 1 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.476
unhealthy, 33.8
n = 29
Health Status: unhealthy
Condition: Central nervous system toxoplasmosis
Age Group: 33.8
Sex: M+F
Population Size: 29
Sources: Page: p.476
Disc. AE: Skin rash, Neutropenia...
AEs leading to
discontinuation/dose reduction:
Skin rash (grade 3, 17.24%)
Neutropenia (grade 3, 3.45%)
Acute renal failure (grade 3, 6.9%)
Sources: Page: p.476
AEs

AEs

AESignificanceDosePopulation
Malaise 23%
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Creatinine serum increased 5%
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Diarrhea 5%
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Elevated liver enzyme levels 5%
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Thrombopenia 9%
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Distress gastrointestinal grade 3, 5%
Disc. AE
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Skin rash grade 3, 5%
Disc. AE
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Stenocardia grade 3, 5%
Disc. AE
4 g 1 times / day steady, oral
Recommended
Dose: 4 g, 1 times / day
Route: oral
Route: steady
Dose: 4 g, 1 times / day
Co-administed with::
pyrimethamine(50 mg oral; 1/day)
folinic acid(15 mg oral; 1/day)
Sources: Page: p.36, 38
unhealthy, 16 - 80
n = 22
Health Status: unhealthy
Condition: Ocular toxoplasmosis
Age Group: 16 - 80
Sex: M+F
Population Size: 22
Sources: Page: p.36, 38
Febrile neutropenia 1.16%
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Skin rash 1.16%
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Neutropenia 18.75%
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Stevens Johnson syndrome grade 3, 1.16%
Disc. AE
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Major bleed grade 4, 25%
Disc. AE
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Thrombocytopenia grade 4, 25%
Disc. AE
1 g 4 times / day steady, oral
Recommended
Dose: 1 g, 4 times / day
Route: oral
Route: steady
Dose: 1 g, 4 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.4
unhealthy, 29.81
n = 16
Health Status: unhealthy
Condition: Cerebral toxoplasmosis
Age Group: 29.81
Sex: M+F
Population Size: 16
Sources: Page: p.4
Skin rash grade 3, 17.24%
Disc. AE
6 g 1 times / day steady, oral (max)
Recommended
Dose: 6 g, 1 times / day
Route: oral
Route: steady
Dose: 6 g, 1 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.476
unhealthy, 33.8
n = 29
Health Status: unhealthy
Condition: Central nervous system toxoplasmosis
Age Group: 33.8
Sex: M+F
Population Size: 29
Sources: Page: p.476
Neutropenia grade 3, 3.45%
Disc. AE
6 g 1 times / day steady, oral (max)
Recommended
Dose: 6 g, 1 times / day
Route: oral
Route: steady
Dose: 6 g, 1 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.476
unhealthy, 33.8
n = 29
Health Status: unhealthy
Condition: Central nervous system toxoplasmosis
Age Group: 33.8
Sex: M+F
Population Size: 29
Sources: Page: p.476
Acute renal failure grade 3, 6.9%
Disc. AE
6 g 1 times / day steady, oral (max)
Recommended
Dose: 6 g, 1 times / day
Route: oral
Route: steady
Dose: 6 g, 1 times / day
Co-administed with::
pyrimethamine(50-75 mg oral; 1/day)
Sources: Page: p.476
unhealthy, 33.8
n = 29
Health Status: unhealthy
Condition: Central nervous system toxoplasmosis
Age Group: 33.8
Sex: M+F
Population Size: 29
Sources: Page: p.476
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes [IC50 6.65 uM]
Drug as victim
PubMed

PubMed

TitleDatePubMed
[New trends in ocular toxoplasmosis--the review].
2001
Flamazine is not a debriding agent.
2001 Aug 9-Sep 12
[Drug hypersensitivity syndrome rapidly resolving after human immunoglobulin infusion].
2001 Dec
Enhanced anti-Shigella activity of erythromycin supplemented with sulfadiazine.
2001 Dec
Pentadecapeptide BPC 157 cream improves burn-wound healing and attenuates burn-gastric lesions in mice.
2001 Dec
Development of an artificial dermis preparation capable of silver sulfadiazine release.
2001 Dec 5
Matrix solid-phase dispersion extraction and high-performance liquid chromatographic determination of residual sulfonamides in chicken.
2001 Dec 7
Antimicrobial susceptibility of starter culture bacteria used in Norwegian dairy products.
2001 Jul 20
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
Management of pressure ulcers.
2001 Nov
Winston Churchill and M & B.
2001 Nov
Safety and efficacy of an improved antiseptic catheter impregnated intraluminally with chlorhexidine.
2001 Nov-Dec
In vitro and in vivo efficacy of catheters impregnated with antiseptics or antibiotics: evaluation of the risk of bacterial resistance to the antimicrobials in the catheters.
2001 Oct
Antimicrobial-coated/bonded and -impregnated intravascular catheters.
2001 Oct
Suspected protozoal myeloencephalitis in a two-month-old colt.
2001 Sep 1
The beneficial toxicity paradox of antimicrobials in leg ulcer healing impaired by a polymicrobial flora: a proof-of-concept study.
2002
Determination of selected sulfonamide antibiotics and trimethoprim in manure by electrospray and atmospheric pressure chemical ionization tandem mass spectrometry.
2002
[A case of primary pyoderma-like aspergillosis occurring in a patient with a cervical spinal cord injury].
2002
Submaxillary adenopathy as sole manifestation of toxoplasmosis: case report and literature review.
2002 Apr
Prevalence of moderate penicillin resistant invasive Neisseria meningitidis infection in Scotland, 1994-9.
2002 Apr
Transfer and distribution profiles of dietary sulphonamides in the tissues of the laying hen.
2002 Apr
Quantification of veterinary antibiotics (sulfonamides and trimethoprim) in animal manure by liquid chromatography-mass spectrometry.
2002 Apr 5
New simple liquid chromatographic method for the determination of trimethoprim, sulfadiazine and N4-acetylsulfadiazine in plasma of broilers.
2002 Apr 5
Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000.
2002 Aug
[Increased serum and urinary levels of silver during treatment with topical silver sulfadiazine].
2002 Feb
[Congenital toxoplasmosis: prevention in the pregnant woman and management of the neonate].
2002 Feb
Comparison of propolis skin cream to silver sulfadiazine: a naturopathic alternative to antibiotics in treatment of minor burns.
2002 Feb
Deep partial thickness burn after contact with a Meal Ready-To-Eat heater.
2002 Feb
Effects of silver sulphadiazine on the production of exoproteins by Staphylococcus aureus.
2002 Jan
Evaluation of an antimicrobial-impregnated continuous ambulatory peritoneal dialysis catheter for infection control in rats.
2002 Jan
Atypical anterior optic neuropathy caused by toxoplasmosis.
2002 Jan
Complete osseous regeneration of a large skull defect in a patient with cutis aplasia: a conservative approach.
2002 Jul
An update on current practices in the management of ocular toxoplasmosis.
2002 Jul
A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis.
2002 Jul
An infection-preventing bilayered collagen membrane containing antibiotic-loaded hyaluronan microparticles: physical and biological properties.
2002 Jul
The effectiveness of processed grapefruit-seed extract as an antibacterial agent: I. An in vitro agar assay.
2002 Jun
Anal canal amputation and necrosis of the anal sphinchter due to electric current injury.
2002 Jun
Laminin modified infection-preventing collagen membrane containing silver sulfadiazine-hyaluronan microparticles.
2002 Jun
In vitro activities of pentamidine, pyrimethamine, trimethoprim, and sulfonamides against Aspergillus species.
2002 Jun
Silver-coated endotracheal tubes associated with reduced bacterial burden in the lungs of mechanically ventilated dogs.
2002 Mar
Is a silver coating a silver lining?
2002 Mar
Iminodibenzyl as a novel coupling agent for the spectrophotometric determination of sulfonamide derivatives.
2002 Mar
[Topical agents used in the treatment of burns].
2002 Mar-Apr
[Glanders--a potential disease for biological warfare in humans and animals].
2002 May
Folate deficiency during treatment with orally administered folic acid, sulphadiazine and pyrimethamine in a horse with suspected equine protozoal myeloencephalitis (EPM).
2002 May
Silver. 2: Toxicity in mammals and how its products aid wound repair.
2002 May
Confocal laser microscopic observation of glycocalyx production by Staphylococcus aureus in vitro.
2002 May
Unsuspected Toxoplasma gondii empyema in a bone marrow transplant recipient.
2002 May 1
Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. AIDS Clinical Trials Group 237/Agence Nationale de Recherche sur le SIDA, Essai 039.
2002 May 1
Effect of sulfadiazine and pyrimethamine on selected physiologic and performance parameters in athletically conditioned thoroughbred horses during an incremental exercise stress test.
2002 Spring
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Can also be used topically http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&ApplNo=018810&DrugName=THERMAZENE&ActiveIngred=SILVER%20SULFADIAZINE&SponsorApplicant=THEPHARMANETWORK%20LLC&ProductMktStatus=1&goto=Search.DrugDetails
Usual Adult Dose for Toxoplasmosis Toxoplasmic encephalitis: Initial dose: Pyrimethamine 200 mg orally once Maintenance dose: <60 kg: Sulfadiazine 1 g orally every 6 hours plus pyrimethamine 50 mg orally once a day. >=60 kg: Sulfadiazine 1500 mg orally every 6 hours plus pyrimethamine 75 mg orally once a day. In addition, leucovorin 10 to 20 mg/day orally (may increase up to 50 mg/day).
Route of Administration: Oral
Sulfadiazine inhibited Pseudomonas aeruginosa with MIC 256 ug/mL
Substance Class Chemical
Created
by admin
on Sat Dec 16 06:41:11 GMT 2023
Edited
by admin
on Sat Dec 16 06:41:11 GMT 2023
Record UNII
5FE7HP0JMG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SULFADIAZINE ZINC
Common Name English
Zinc Sulfadiazine [WHO-DD]
Common Name English
ZINC SULFADIAZINE
WHO-DD  
Common Name English
BENZENESULFONAMIDE, 4-AMINO-N-2-PYRIMIDINYL-, ZINC SALT (2:1)
Common Name English
Code System Code Type Description
PUBCHEM
152849
Created by admin on Sat Dec 16 06:41:11 GMT 2023 , Edited by admin on Sat Dec 16 06:41:11 GMT 2023
PRIMARY
FDA UNII
5FE7HP0JMG
Created by admin on Sat Dec 16 06:41:11 GMT 2023 , Edited by admin on Sat Dec 16 06:41:11 GMT 2023
PRIMARY
CAS
69858-60-2
Created by admin on Sat Dec 16 06:41:11 GMT 2023 , Edited by admin on Sat Dec 16 06:41:11 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY